BGF joined Cellular Origins' Series A, bringing the round's total funding to $40 million.
Cellular Origins is enabling the manufacture of cell therapies at scale through a flexible, factory-led automation platform that adapts to existing processes and facilities
Cellular Origins is enabling the manufacture of cell therapies at scale through a flexible, factory-led automation platform that adapts to existing processes and facilities. Its Constellation ecosystem unites mobile robotics and automated sterile welding with proven bioprocess instruments, eliminating the need for therapy redevelopment and providing a dependable route from clinical to commercial manufacture.